<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Estradiol (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Estradiol (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Estradiol (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9120" href="/d/html/9120.html" rel="external">see "Estradiol (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="11674" href="/d/html/11674.html" rel="external">see "Estradiol (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8018272"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Endometrial cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) (0.625 mg) alone, relative to placebo. Do not use estrogen-alone therapy for the prevention of cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo. Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Breast cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dementia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women ≥65 years of age during 5.2 years of treatment with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. Do not use estrogen-alone therapy for the prevention of dementia.</p>
<p style="text-indent:-2em;margin-left:2em;">The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women ≥65 years of age during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. Do not use estrogen plus progestogen therapy for the prevention of dementia.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk vs benefits:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Only daily oral CEs (0.625 mg) and daily oral CE (0.625 mg) and MPA (2.5 mg) were studied in the estrogen-alone and estrogen plus progestin substudies of the WHI, respectively. Therefore, the relevance of the WHI findings regarding the adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen alone products is not known. Likewise, the relevance of the WHI findings regarding the adverse cardiovascular events, dementia, and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of the risks for other products. Discuss with your patient the benefits and risks of estrogen-alone or estrogen plus progestogen therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Secondary exposure (Evamist):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure to Evamist by women using this product. In most cases, the condition resolved with removal of Evamist exposure. Women should ensure that children do not come into contact with the site(s) where Evamist is applied. Health care providers should advise patients to strictly adhere to recommended instructions for use.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8018338"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alora;</li>
<li>Climara;</li>
<li>Delestrogen;</li>
<li>Depo-Estradiol;</li>
<li>Divigel;</li>
<li>Dotti;</li>
<li>Elestrin;</li>
<li>Estrace;</li>
<li>Estrogel;</li>
<li>Evamist;</li>
<li>Femring;</li>
<li>Lyllana;</li>
<li>Menostar;</li>
<li>Minivelle;</li>
<li>Vivelle-Dot</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869134"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Climara 25;</li>
<li>Climara 50;</li>
<li>Climara 75;</li>
<li>Divigel;</li>
<li>Estradot 100;</li>
<li>Estradot 25;</li>
<li>Estradot 37.5;</li>
<li>Estradot 50;</li>
<li>Estradot 75;</li>
<li>Estrogel;</li>
<li>Lupin-Estradiol;</li>
<li>Oesclim;</li>
<li>PMS-Estradiol;</li>
<li>SANDOZ Estradiol Derm 100;</li>
<li>SANDOZ Estradiol Derm 50;</li>
<li>SANDOZ Estradiol Derm 75</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10824233"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Estrogen Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812608"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Estrasorb has been discontinued in the US for more than 1 year. Use lowest effective dose for shortest duration possible that is consistent with an individual's treatment goals and risks; all dosage needs to be adjusted based upon the patient's response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7471abe8-bd58-44ac-b865-e47b18736eb5">Constitutional delay of growth and puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constitutional delay of growth and puberty (CDGP) (females):</b> Limited data available: Children ≥12 years and Adolescents: <b>Note:</b> Begin with the lowest available dose and gradually increase. Obtain bone age every 6 months to avoid premature epiphyseal closure. If treatment continues beyond 1 year or breast growth is significant and has plateaued or breakthrough bleeding occurs, add cyclic progesterone. Continue until menstruation has been established, or longer if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078','lexi-content-ref-Santos.1','lexi-content-ref-Sperling.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078','lexi-content-ref-Santos.1','lexi-content-ref-Sperling.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral (micronized, Estrace): Initial dose: 5 mcg/kg once daily; after 6 to 12 months of therapy, may increase to 10 mcg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078'])">Ref</a></span>). Using currently available dosage forms, some have recommended starting at a fixed dose of 0.25 mg once daily (1/2 of the 0.5 mg tablet) and increasing to 0.5 mg once daily after 6 to 12 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: Initial dose: 3.1 to 6.2 mcg/day patch (eg, <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>4</sub> of a 25 mcg/day patch), apply at night, remove in the morning. Increase by 3.1 to 6.2 mcg/day patch every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078'])">Ref</a></span>). <b>Note:</b> The practice of cutting patches to achieve low doses is cited frequently in the literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11443165','lexi-content-ref-20375216','lexi-content-ref-19226267','lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11443165','lexi-content-ref-20375216','lexi-content-ref-19226267','lexi-content-ref-22296078'])">Ref</a></span>); however, product specific data may not be available for all transdermal products due to product availability/manufacturing changes.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d05edaaa-6221-444e-8c47-d3f9e2c337bd">Hypogonadism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypogonadism (females):</b> Limited data available: Children ≥12 years and Adolescents: <b>Note:</b> Begin with the lowest available dose and gradually increase. Obtain bone age every 6 months to avoid premature epiphyseal closure. Once breast growth is significant and has plateaued or breakthrough bleeding occurs, add cyclic progesterone. Continue until menstruation has been established, or longer if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078','lexi-content-ref-Sperling.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078','lexi-content-ref-Sperling.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral (micronized): Initial dose: 5 mcg/kg once daily for 6 to 12 months; may then increase to 10 mcg/kg/day for 6 to 12 months; dose may be increased at every 6 to 12 month intervals by 5 mcg/kg/day, up to 20 mcg/kg/day. Do not exceed adult dose of 2 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: Initial dose: 3.1 to 6.2 mcg/day patch (eg, <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>4</sub> of a 25 mcg/day patch), apply at night, remove in the morning. Increase by 3.1 to 6.2 mcg/day patch every 6 months; Do not exceed adult dose of 50 to 100 mcg/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078'])">Ref</a></span>). Note: The practice of cutting patches to achieve low doses is cited frequently in the literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11443165','lexi-content-ref-20375216','lexi-content-ref-19226267','lexi-content-ref-22296078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11443165','lexi-content-ref-20375216','lexi-content-ref-19226267','lexi-content-ref-22296078'])">Ref</a></span>); however, product specific data may not be available for all transdermal products due to product availability/manufacturing changes.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5e6cbb8-2619-46d9-9bba-b4c59c48b5ce">Turner syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Turner syndrome (females):</b> Limited data available: Children ≥12 years and Adolescents: Begin at ~12 years of age using a low dose and gradually increase dose over 2 to 4 years to full adult dose. After 2 years of estrogen or when breakthrough bleeding occurs, add cyclic progesterone. <b>Note:</b> Full dose estrogen will be needed until at least age 30 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17047017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17047017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Cypionate (Depot-Estradiol): Initial: 0.2 to 0.4 mg every 4 weeks, slowly increase dose over about 2 years to the goal adult dose: 3 mg/month; one trial started at 0.2 mg/dose, then increased dose at 6 month intervals in 0.2 mg/dose increments until dose of 1 mg reached and then increased in 0.5 mg/dose increments thereafter to a final dose of 3 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17047017','lexi-content-ref-16189255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17047017','lexi-content-ref-16189255'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral (micronized, Estrace): Initial dose: 5 mcg/kg once daily for the first 2 years, followed by 7.5 mcg/kg for the 3rd year, then 10 mcg/kg thereafter; once final height is attained, increase to adult dose of 1 to 2 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19200215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19200215'])">Ref</a></span>). A fixed dose of 0.25 mg once daily; increasing to the adult dose of 2 to 4 mg/day over the course of 2 years has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17047017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17047017'])">Ref</a></span>). <b>Note:</b> Due to extensive first-pass metabolism, other routes of administration may be preferable.</p>
<p style="text-indent:-2em;margin-left:4em;">Topical gel (Divigel): Initial: 0.1 mg of estradiol once daily for the first year, 0.2 mg of estradiol once daily for the second year, 0.5 mg of estradiol once daily for the third year, 1 mg of estradiol once daily for the fourth year, and 1.5 mg of estradiol once daily for the fifth year. Dosing based on a trial of 23 girls that followed development for 5 years; long-term dose is unknown. Due to lack of commercially available product for lower doses, individual sachets of 0.1 mg estradiol were prepared (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15240598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15240598'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch: Initial: 6.25 mcg/day patch; slowly increase over about 2 years to the goal adult dose: 100 to 200 mcg/day patch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17047017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17047017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The lowest-dose commercially available patches deliver 14 and 25 μg daily; preferred dose fractionation method has not been established (eg, administering a partial patch, limiting to overnight use, or administering whole patches for 7 to 10 days per month). Product specific data may not be available for splitting/cutting some transdermal patches; one center has used the following titration method using Vivelle-Dot product (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20375216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20375216'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Treatment month:</p>
<p style="text-indent:-2em;margin-left:10em;">0 to &lt;6 months of treatment: 3.125 mcg to 4.17 mcg/dose (equals <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>6</sub> of a 25 mcg/day patch), apply at night, remove in the morning (not continuous)</p>
<p style="text-indent:-2em;margin-left:10em;">6 to &lt;12 months of treatment: 3.125 mcg to 4.17 mcg/dose (equals <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>6</sub> of a 25 mcg/day patch) apply twice weekly (continuous)</p>
<p style="text-indent:-2em;margin-left:10em;">12 to &lt;18 months of treatment: 6.25 mcg to 8.33 mcg/dose (equals <sup>1</sup>/<sub>4</sub> to <sup>1</sup>/<sub>3</sub> of a 25 mcg/day patch), apply twice weekly (continuous)</p>
<p style="text-indent:-2em;margin-left:10em;">18 to &lt;24 months of treatment: 12.5 mcg/dose (equals <sup>1</sup>/<sub>2</sub> of a 25 mcg/day patch), apply twice weekly (continuous)</p>
<p style="text-indent:-2em;margin-left:10em;">≥24 months of treatment: 25 mcg/day patch, apply twice weekly (continuous); then increase by one patch strength every 6 months to a final goal of 100 mcg/day continuously</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729711"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">For most products, there are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F52729712"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">For most products, there are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use is contraindicated with hepatic dysfunction or disease.</p></div>
<div class="block doa drugH1Div" id="F8018394"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9120" href="/d/html/9120.html" rel="external">see "Estradiol (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8423721-7a23-4fed-bf36-91a0c75f98e6">Breast cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic:</b>
<b>Oral</b> (Estrace): Males and postmenopausal females: 10 mg 3 times/day for at least 3 months or (off-label dosing) postmenopausal females: 2 mg 3 times/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19690310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19690310'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a229ff4e-4050-4b68-9db4-24f5df7a8b37">Hormone therapy for transgender females, monotherapy or combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hormone therapy for transgender females (assigned male at birth), monotherapy or combination therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Alternative routes of administration (eg, sublingual administration of the oral tablet) may be used by some centers (limited data; additional study needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34781041','lexi-content-ref-30957961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34781041','lexi-content-ref-30957961'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Usual dosage:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b></p>
<p style="text-indent:0em;margin-left:6em;">Estradiol cypionate: 2 to 10 mg every week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Estradiol valerate: 5 to 30 mg every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 2 to 6 mg/day administered once daily or divided twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320642','lexi-content-ref-28159148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320642','lexi-content-ref-28159148'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> Estradiol cypionate or estradiol valerate: 3 to 4 mg every week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36868378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36868378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transdermal:</b> Apply 0.025 to 0.2 mg/day patch every 3 to 5 days. <b>Note: </b>Apply two 0.1 mg patches to create a 0.2 mg/day dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> Adjust dose with a goal of elevating serum estradiol levels and suppressing serum testosterone levels into the normal female range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdf1e035-dfe9-427e-9d57-84e89b0136ec">Osteoporosis, postmenopausal, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, prevention (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an alternative to first-line therapies to prevent bone loss in patients with moderate to severe vasomotor symptoms of menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-34448749','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-34448749','lexi-content-ref-25182228'])">Ref</a></span>). In patients <b>without</b> menopausal vasomotor symptoms who require fracture risk reduction, other first-line therapies are preferred. Avoid initiating in patients &gt;60 years of age or who are &gt;10 years beyond menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448749','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448749','lexi-content-ref-25182228'])">Ref</a></span>). Ensure adequate calcium and vitamin D intake during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Initial dose and dosage adjustments are individualized based on menopausal symptoms. Transdermal doses ≥0.025 mg/day have been associated with BMD benefits; separate therapy to reduce the risk of osteoporotic fractures is not required for patients who attain bone mineral density (BMD) targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Alora, Minivelle, Vivelle-Dot: Initial: Apply 0.025 mg/day patch <i>twice</i> weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Climara: Initial: Apply 0.025 mg/day patch <i>once</i> weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Estradot [Canadian product]: There are no specific initial dosage recommendations provided in the manufacturer's labeling; a minimum effective dose of one 0.025 mg/day patch applied <i>twice</i> weekly has been established off label (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12941676','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12941676','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Menostar: Apply 0.014 mg/day patch <i>once</i> weekly. In patients with a uterus, also administer a progestin for 14 days every 6 to 12 months. <b>Note:</b> Although this dosage resulted in modest BMD benefits, the effect may be greatest in patients with low baseline endogenous estrogen levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15339752','lexi-content-ref-17620054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15339752','lexi-content-ref-17620054'])">Ref</a></span>). Additional antiresorptive therapy (eg, with a bisphosphonate) may be needed based on BMD response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral </b>(Estrace): Initial dose and dosage adjustments are individualized based on menopausal symptoms. Oral doses ≥0.5 mg/day have been associated with BMD benefits; separate therapy to reduce the risk of osteoporotic fractures is not required for patients who attain BMD targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosen.1'])">Ref</a></span>). The lowest effective dose has not been determined; estradiol increases BMD in a dose-dependent fashion, with higher doses (eg, 0.5 to 1 mg/day) associated with greater BMD increases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16278618','lexi-content-ref-34448749','lexi-content-ref-12941676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16278618','lexi-content-ref-34448749','lexi-content-ref-12941676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> The optimal duration of therapy has not been established. Estrogens should be used for the shortest duration possible consistent with treatment goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-25182228','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-25182228','lexi-content-ref-Manu.1'])">Ref</a></span>). Extended use may be considered in patients in whom alternative therapies are not appropriate and when benefits of therapy are expected to outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Discontinuation of therapy:</b> If continued osteoporosis therapy is necessary, switch to antiresorptive therapy (eg, with a bisphosphonate) following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448749','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448749','lexi-content-ref-25182228'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13531fc0-f759-4ce8-adf1-0f2fb51f128a">Prostate cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Valerate (Delestrogen): 30 mg or more every 1 to 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (Estrace): 1 to 2 mg 3 times/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33847005-a8a0-48f0-b6fe-f3530ab1256e">Secondary amenorrhea, hypoestrogenism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary amenorrhea, hypoestrogenism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For functional hypothalamic amenorrhea (FHA), initiate only if menses have not returned after 6 to 12 months of nonpharmacologic (eg, behavioral, lifestyle) therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28368518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28368518'])">Ref</a></span>). For hypoestrogenism due to other causes (eg, primary ovarian insufficiency), may initiate after diagnosis confirmed if no contraindications (eg, breast cancer). For patients with a uterus, give estrogen with either cyclical (preferred in FHA) or continuous progestogen (ie, a natural progesterone or synthetic progestin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28426619','lexi-content-ref-28368518','lexi-content-ref-19196677','lexi-content-ref-24905063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28426619','lexi-content-ref-28368518','lexi-content-ref-19196677','lexi-content-ref-24905063'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>
<b>: </b>1 to 2 mg per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28426619','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28426619','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal: </b>0.1 mg per day patch applied once weekly (Climara) or twice weekly (Alora, Vivelle-Dot) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30301734','lexi-content-ref-31603998','lexi-content-ref-28426619','lexi-content-ref-24463911','lexi-content-ref-19196677','lexi-content-ref-17509587','lexi-content-ref-24905063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30301734','lexi-content-ref-31603998','lexi-content-ref-28426619','lexi-content-ref-24463911','lexi-content-ref-19196677','lexi-content-ref-17509587','lexi-content-ref-24905063'])">Ref</a></span>). <b>Note:</b> For twice-weekly dosing, replace patch every 3 to 4 days. When switching from oral to transdermal therapy, start transdermal patch 1 week after discontinuing oral hormone (may begin sooner if symptoms reappear within 1 week).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b>
<b>Note:</b> IM route of administration is considered nonpreferred to oral or transdermal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Welt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Welt.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cypionate (Depo-Estradiol): 1.5 to 2 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Valerate (Delestrogen): 10 to 20 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b>If amenorrhea is expected to be transient (eg, FHA), discontinue after ~18 months to assess for recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30301734','lexi-content-ref-31603998','lexi-content-ref-28368518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30301734','lexi-content-ref-31603998','lexi-content-ref-28368518'])">Ref</a></span>). If amenorrhea is expected to be permanent (eg, primary ovarian insufficiency), continue at least until the average age of natural menopause (age ~50 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28426619','lexi-content-ref-10818427','lexi-content-ref-19196677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28426619','lexi-content-ref-10818427','lexi-content-ref-19196677'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause: </b>
<b>Note<i>:</i></b>For use in symptomatic patients who are &lt;60 years of age or within 10 years of menopause who do not have contraindications to hormone therapy (eg, breast cancer) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). Nonoral estrogen preparations are preferred in patients with hypertriglyceridemia, risk factors for venous thromboembolic disease, active gallbladder disease, and/or migraine headache with aura (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1','lexi-content-ref-20230416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1','lexi-content-ref-20230416'])">Ref</a></span>). Initiate at the lowest dose and increase approximately every 4 weeks as needed to relieve symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1'])">Ref</a></span>). Evaluate routinely to minimize drug exposure and optimize administration route. Younger patients (eg, bilateral oophorectomy) may require higher doses. In patients with a uterus, give estrogen with a progestogen (ie, a natural progesterone or synthetic progestin), dosed either cyclically (preferred in late menopausal transition or early postmenopause) or continuously (preferred if &gt;2 to 3 years postmenopause) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1','lexi-content-ref-35797481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (Estrace): Initial: 0.5 to 1 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24463691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24463691'])">Ref</a></span>). Dosage range: 0.5 to 2 mg per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26444994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26444994'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical gel:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Divigel: Initial: 0.25 g per day. Dosage range: 0.25 to 1.25 g per day (equivalent to estradiol 0.25 to 1.25 mg per day); maximum: 1.25 g per day.</p>
<p style="text-indent:-2em;margin-left:6em;">Elestrin: Initial: Apply 1 pump (0.87 g) at the same time each day (equivalent to estradiol 0.52 mg per day).</p>
<p style="text-indent:-2em;margin-left:6em;">EstroGel: Apply 1 pump (1.25 g) at the same time each day (equivalent to estradiol 0.75 mg per day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical spray:</b> Initial: 1 spray (estradiol 1.53 mg) per day. Dosing range: 1 to 3 sprays per day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal</b>: <b>Note:</b> For twice-weekly dosing, replace patch every 3 to 4 days. When switching from oral to transdermal therapy, start transdermal patch 1 week after discontinuing oral hormone (may begin sooner if symptoms reappear within 1 week). When switching from other topical therapy, no waiting period is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Alora, Estradot [Canadian product]: Initial: Apply 0.025 mg per day patch <i>twice</i> weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1','lexi-content-ref-35797481'])">Ref</a></span>). Dosage range: 0.025 to 0.1 mg per day patch twice weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Climara: Initial: Apply 0.025 mg per day patch <i>once</i> weekly. Dosage range: 0.025 to 0.1 mg per day patch once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Minivelle, Vivelle-Dot: Initial: Apply 0.025 mg/day patch <i>twice</i> weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.1','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.1','lexi-content-ref-35797481'])">Ref</a></span>). Dosage range: 0.025 to 0.1 mg per day patch twice weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Oesclim [Canadian product]: Initial: Apply 0.025 to 0.05 mg per day patch <i>twice</i> weekly. Dosage range: 0.025 to 0.1 mg per day patch twice weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Vaginal ring</b> (Femring): Initial: 0.05 mg per day intravaginally every 3 months. Dosage range: 0.05 to 0.1 mg per day intravaginally every 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b>
<b>Note:</b> IM route of administration is considered nonpreferred to other routes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martin.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martin.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cypionate (Depo-Estradiol): 1 to 5 mg every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Valerate (Delestrogen): 10 to 20 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer and with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3679489c-0513-47c2-abaf-018b39b0ff61">Vulvar and vaginal atrophy associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar and vaginal atrophy associated with menopause: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM</b>: Valerate (Delestrogen): 10 to 20 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intravaginal</b>: Vaginal ring (Femring): Initial: 0.05 mg intravaginally; following insertion, dose is released daily for 3 months. Usual dose: 0.05 mg to 0.1 mg intravaginally every 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (Estrace): 0.5 to 1 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24463691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24463691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical gel</b> (EstroGel): 1.25 g/day applied at the same time each day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal</b>
<b>:</b>
<b>No</b>
<b>te:</b> Indicated dose may be used continuously in patients without a uterus. Continuous or cyclic schedules (3 weeks on, 1 week off) may be used in patients with a uterus (indication and product specific; refer to manufacturer's labeling). When changing patients from oral to transdermal therapy, start transdermal patch 1 week after discontinuing oral hormone (may begin sooner if symptoms reappear within 1 week). Adjust dose as necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Alora: Initial: Apply 0.05 mg/day patch <i>twice</i> weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Climara: Initial: Apply 0.025 mg/day patch <i>once</i> weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Vivelle-Dot: Initial: Apply 0.0375 mg/day patch <i>twice </i>weekly.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991819"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">For most products, there are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989098"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated with hepatic dysfunction or disease</p></div>
<div class="block arsc drugH1Div" id="F58757515"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Breast cancer</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There is an increased risk of breast cancer (ie, <b>malignant neoplasm of breast</b>) with menopausal hormone therapy (MHT) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332','lexi-content-ref-35797481','lexi-content-ref-33115755','lexi-content-ref-35418701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332','lexi-content-ref-35797481','lexi-content-ref-33115755','lexi-content-ref-35418701'])">Ref</a></span>). The use of estrogen-only therapy (ET) for &lt;1 year is considered low risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332','lexi-content-ref-33115755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332','lexi-content-ref-33115755'])">Ref</a></span>). Multiple studies, including the Women’s Health Initiative (WHI), show a higher risk of breast cancer with combined estrogen-progesterone therapy (EPT) versus ET regimens (continuous exposure &gt; intermittent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-33115755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-33115755'])">Ref</a></span>). Data indicate risk with EPT may be doubled versus ET; a trend continued at 20 years follow-up in WHI participants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-33115755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-33115755'])">Ref</a></span>). Cessation of MHT rapidly decreases risk, but increased risk of breast cancer may persist for up to 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332','lexi-content-ref-33115755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332','lexi-content-ref-33115755'])">Ref</a></span>). MHT did not increase risk in women with genetic risk factors; however, systemic MHT is not recommended in breast cancer survivors (especially those with hormone-receptor positive disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-34731351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-34731351'])">Ref</a></span>). Breast cancer in patients receiving MHT is more likely to be estrogen-receptor positive (ER+) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332'])">Ref</a></span>). In transgender people receiving gender affirming hormone therapy, there does not appear to be an increased risk of breast cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36238954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36238954'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; not clearly established; research continues to identify specific genetic mutations and pathways stimulated by increased estrogen levels, leading to accelerated proliferation causing mutagenesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418701'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; increased risk of breast cancer observed with therapy beyond 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332','lexi-content-ref-33115755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332','lexi-content-ref-33115755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use; highest risk with &gt;5 years of MHT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332','lexi-content-ref-35797481','lexi-content-ref-33115755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332','lexi-content-ref-35797481','lexi-content-ref-33115755'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Systemic dosage forms; nonoral routes may confer less risk, but no clinical trials have been designed to examine this outcome (NAMS 2022). Topical vaginal estrogen is associated with little risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of combination MHT regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31474332','lexi-content-ref-35797481','lexi-content-ref-33115755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31474332','lexi-content-ref-35797481','lexi-content-ref-33115755'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dementia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of hormone replacement therapy (HRT) as prevention or treatment for decline in cognitive function, dementia, and/or Alzheimer disease is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-34588168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-34588168'])">Ref</a></span>). Data are mixed for combination menopausal hormone therapy regimens as well as estrogen-only therapy (ET) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-34588168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-34588168'])">Ref</a></span>). The Women’s Health Initiative memory study showed that users of conjugated equine estrogens (CEEs) plus medroxyprogesterone acetate had twice the risk (23/10,000) of all-cause dementia when therapy was initiated at &gt;65 years of age, while users of CEE alone had no increased signs of dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). Estrogen therapy may have protective cognitive benefits in patients who have had a bilateral oophorectomy before the natural age of menopause and do not have any contraindications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; hypotheses include estrogen protection from glutamate toxicity, prevention of β-amyloid–induced cellular changes, and increased/preserved cholinergic activity in the forebrain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34849527','lexi-content-ref-20019127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34849527','lexi-content-ref-20019127'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Decline of cognition at baseline; potential positive outcomes in patients with normal cognition at therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Late menopause; protective exogenous estrogen benefits may be limited to perimenopause and/or early menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34849527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34849527'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Endometrial cancer</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Unopposed estrogen-only therapy (ET) in a postmenopausal patient with an intact uterus is contraindicated due to an increased risk of endometrial cancer (ie, <b>endometrial carcinoma</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23680641','lexi-content-ref-35797481','lexi-content-ref-27451318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23680641','lexi-content-ref-35797481','lexi-content-ref-27451318'])">Ref</a></span>). Systemic ET should be used with an adequate dose of progesterone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). A conjugated equine estrogen (CEE) plus medroxyprogesterone acetate in the Women’s Health Initiative showed equivalent endometrial cancer risk to placebo with a potential reduction in risk at 13 years follow-up (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). It is also acceptable to use a CEE plus bazedoxifene to mitigate endometrial cancer risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). There is no increased risk of endometrial cancer with low-dose vaginal estrogen therapy; however, trial data are limited to 1 year duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). After discontinuation of ET, increased risk of endometrial cancer persists for several years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23680641','lexi-content-ref-35797481','lexi-content-ref-27451318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23680641','lexi-content-ref-35797481','lexi-content-ref-27451318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; unopposed estrogen precipitates increased mitotic activity/proliferation of endometrial cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23680641','lexi-content-ref-3358913','lexi-content-ref-27451318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23680641','lexi-content-ref-3358913','lexi-content-ref-27451318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; increased risk of endometrial cancer appears after 2 to 3 years of unopposed ET (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23680641','lexi-content-ref-27451318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23680641','lexi-content-ref-27451318'])">Ref</a></span>). <b>Endometrial hyperplasia</b> occurs within 1 year in 20% of patients receiving unopposed ET (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8178840']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8178840'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23680641','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23680641','lexi-content-ref-35797481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration (highest risk &gt;10 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23680641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23680641'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Unopposed ET with intact uterus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23680641','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23680641','lexi-content-ref-35797481'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Endometriosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Malignant transformation of endometriosis postsurgical intervention has been rarely reported in patients receiving unopposed estrogen-only therapy (ET) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25399218','lexi-content-ref-28498913','lexi-content-ref-34439184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25399218','lexi-content-ref-28498913','lexi-content-ref-34439184'])">Ref</a></span>). Endometrioid adenocarcinoma is the most common diagnosis among these patients; however, the quality of evidence is low and mostly observational (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25399218','lexi-content-ref-28498913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25399218','lexi-content-ref-28498913'])">Ref</a></span>). While most patients responded to oncologic intervention, the carcinoma was fatal in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28498913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28498913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; exogenous estrogen stimulation of remaining endometrial tissue postsurgical intervention, leading to reactivation of tissue proliferation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28498913','lexi-content-ref-34439184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28498913','lexi-content-ref-34439184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; most patients were currently taking unopposed ET when diagnosed; however, several of the malignancies were diagnosed years after menopausal hormone therapy (MHT) discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28498913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28498913'])">Ref</a></span>). Range of onset was 4 months to 20 years with a mean MHT duration of 7.8 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28498913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28498913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Unopposed exogenous estrogen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28498913','lexi-content-ref-34439184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28498913','lexi-content-ref-34439184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous endometriosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34439184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34439184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Incomplete definitive gynecologic surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28498913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28498913'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogen is associated with an increased risk of <b>cholelithiasis</b>, <b>cholecystitis</b>, and cholecystectomy; however, no increased risk of biliary cancer has been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). Despite discontinuation of estrogen-only therapy, the risk of gallbladder disease may persist 10 years later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18617493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18617493'])">Ref</a></span>). Cisgender men and transgender women may be at increased risk of a biliary event, including acute gallstone<b> pancreatitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15657326','lexi-content-ref-33948625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15657326','lexi-content-ref-33948625'])">Ref</a></span>). Any disease of the liver is a contraindication to estrogen use, as endogenous and exogenous sources of estrogen have been associated with liver growth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34153174','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34153174','lexi-content-ref-35797481'])">Ref</a></span>). No increase in liver function tests among transgender adults on hormone therapy has been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28090436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28090436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; first-pass hepatic effects on lipid metabolism in addition to relaxation effects of the gallbladder via G protein–coupled estrogen receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-28383429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-28383429'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33948625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33948625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Oral products pose increased risk, while transdermal products have minimal risk due to bypass of the first-pass hepatic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hysterectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15657326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15657326'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Elevated triglycerides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33948625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33948625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33948625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33948625'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ovarian cancer</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Data related to the risk of ovarian cancer (ie, <b>ovarian carcinoma</b>) with menopausal hormone therapy (MHT) are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31849838','lexi-content-ref-28650869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31849838','lexi-content-ref-28650869'])">Ref</a></span>). The Women’s Health Initiative showed that conjugated equine estrogen plus medroxyprogesterone acetate use after 5.6 years conferred no increased risk, and this trend was continued after 13 years of hormone use. An association has been reported in observational data; however, the risk is small (&lt;1/1000) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28650869','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28650869','lexi-content-ref-35797481'])">Ref</a></span>). Additionally, there is no increased risk of recurrence or death after treatment for ovarian cancer in patients receiving MHT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28650869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28650869'])">Ref</a></span>). Increased ovarian cancer risk may be limited to serous and endometrioid tumors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17179984','lexi-content-ref-31849838','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17179984','lexi-content-ref-31849838','lexi-content-ref-35797481'])">Ref</a></span>). Discontinuation of MHT diminishes risk within 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related, unknown; unopposed estrogen may elicit proliferation and/or abnormal transformation of ovarian cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17179984','lexi-content-ref-27054934','lexi-content-ref-31849838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17179984','lexi-content-ref-27054934','lexi-content-ref-31849838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; in studies showing increased risk, duration of ≥5 years of unopposed estrogen therapy was consistently observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17179984','lexi-content-ref-27054934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17179984','lexi-content-ref-27054934'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy ≥5 years (including past use of ≥5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17179984','lexi-content-ref-27054934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17179984','lexi-content-ref-27054934'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Unopposed estrogen therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17179984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17179984'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;50 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27054934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27054934'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thromboembolic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogen is associated with an increased risk of <b>thromboembolic complications</b> among users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447','lexi-content-ref-31372078','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447','lexi-content-ref-31372078','lexi-content-ref-35797481'])">Ref</a></span>). <b>Venous thromboembolism </b>events (VTEs) of the legs or pulmonary vessels are most common (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372078'])">Ref</a></span>). However, the absolute risk in healthy patients is considered low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447'])">Ref</a></span>). Risk returns to baseline after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447'])">Ref</a></span>). Retrospective data estimate equivalency in risk between transgender women (TGW) and cisgender women at 2 years of estrogen therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29987313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29987313'])">Ref</a></span>). At 8 years of therapy, TGW had a higher risk of thromboembolic events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29987313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29987313'])">Ref</a></span>). Estradiol confers less risk of thromboembolic events than conjugated equine estrogens (CEEs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30626577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30626577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; estrogens are known to be prothrombotic, but the specific hemostatic pathway affected has not been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447'])">Ref</a></span>). Increase in factors VII, VIII, X, prothrombin, and fibrinogen, as well as decrease in antithrombin and protein S, are potential etiologies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29987313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29987313'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; usually develops within the first few months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-30626577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-30626577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy; data suggest increased risk of VTE after 1 to 2 years and increased stroke risk after 7 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372078','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372078','lexi-content-ref-35797481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Estrogen product; estradiol confers less risk than CEE (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30626577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30626577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Current smoker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447','lexi-content-ref-31372078','lexi-content-ref-30626577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447','lexi-content-ref-31372078','lexi-content-ref-30626577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypercholesteremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372078'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447','lexi-content-ref-31372078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447','lexi-content-ref-31372078'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ischemic heart disease/prior myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447','lexi-content-ref-35797481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Stroke (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447','lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447','lexi-content-ref-35797481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Migraine with aura (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Surgery/immobilization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372078'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Thrombophilia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447','lexi-content-ref-31372078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447','lexi-content-ref-31372078'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Strong family history of VTE without identifiable cause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior thromboembolic event (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481','lexi-content-ref-30626577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481','lexi-content-ref-30626577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Less than 21 days postpartum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372078'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Route of administration; oral products may confer more risk than transdermal products; however, trials have not been designed to detect differences in routes of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372078','lexi-content-ref-35797481','lexi-content-ref-30626577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372078','lexi-content-ref-35797481','lexi-content-ref-30626577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use as feminizing therapy in TGW may increase risk when compared to use as menopausal hormone therapy in cisgender women (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450447','lexi-content-ref-29987313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450447','lexi-content-ref-29987313'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8018351"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (transdermal: 10% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (oral: 2%; transdermal: 6% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breakthrough bleeding (transdermal: 6% to 11%), breast tenderness (3% to 17%), endometrium disease (15%), leukorrhea (transdermal: 2% to 11%), mastalgia (including discomfort; transdermal: 5% to 35%), vulvovaginal candidiasis (intravaginal: 6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site erythema (transdermal: ≤17%), application-site irritation (transdermal: ≤17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (transdermal: 1% to 11%), headache (intravaginal, oral, topical: 3% to 12%; transdermal: 13% to 50%), pain (transdermal: 6% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (topical, transdermal: 4% to 12%), back pain (intravaginal, transdermal: 6% to 11%; topical: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (topical, transdermal: 4% to 20%), sinus headache (transdermal: 9% to 11%), sinusitis (intravaginal, transdermal: 4% to 13%), upper respiratory tract infection (topical: 6%; transdermal: 9% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (transdermal: 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (transdermal: 3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (oral: 2%), pruritus (transdermal: 7%), skin rash (transdermal: 7% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hirsutism (transdermal: 2% to 5%), hot flash (transdermal: 6%), intermenstrual bleeding (intravaginal, oral: 2% to 10%), weight gain (transdermal: 4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (intravaginal: 7%), constipation (transdermal: 4% to 7%), dyspepsia (transdermal: 3% to 9%), flatulence (transdermal: 3% to 7%), gastroenteritis (transdermal: 3% to 4%), nausea (transdermal: 4% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal uterine bleeding (topical: 4% to 10%), breast hypertrophy (transdermal: 7%), cervical polyp (transdermal: 6%), dysmenorrhea (transdermal: 7%), genital pruritus (oral: 1% to 2%), nipple pain (topical: 1% to 7%), urinary tract infection (intravaginal: 4%), uterine pain (intravaginal: 2% to 5%), vaginal discharge (oral: ≤4%), vaginal hemorrhage (oral: 3% to 7%), vaginal mycosis (topical: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (transdermal: 3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (topical: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (transdermal: 4% to 6%), asthenia (transdermal: 8%), dizziness (transdermal: 5% to 8%), fatigue (oral: 2%), migraine (transdermal: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (transdermal: 7% to 8%), myalgia (transdermal: 5%), neck pain (transdermal: 3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (transdermal: 6%), flu-like symptoms (transdermal: 8%), paranasal sinus congestion (transdermal: 7%), pharyngitis (transdermal: 7%), rhinitis (transdermal: 2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Cyst (transdermal: 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, altered blood pressure, chest discomfort, chest pain, deep vein thrombosis (Laliberte 2018), irregular pulse, palpitations, peripheral edema, portal vein thrombosis, premature ventricular contractions, pulmonary embolism (Laliberte 2018), tachycardia, thrombophlebitis, thrombosis (including thromboembolic complications) (Vinogradova 2019), unstable angina pectoris, varicose veins, venous thromboembolism (Vinogradova 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, chloasma, contact dermatitis, dyschromia, erythema multiforme (can be application site), erythema nodosum (can be application site), erythema of skin, hemorrhagic eruption of the skin, hyperhidrosis, night sweats, pruritic rash, skin discoloration (including nipple and areola discoloration), swelling of skin, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, change in libido, change in menstrual flow (alterations in frequency and flow of bleeding patterns), exacerbation of porphyria, fibrocystic breast changes, galactorrhea not associated with childbirth, gynecomastia, heavy menstrual bleeding, hypercholesterolemia, hypocalcemia, impaired glucose tolerance, increased serum triglycerides, loss of libido, menopausal symptoms, spotting, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, bloating, cholecystitis, cholelithiasis, decreased appetite, diarrhea, dysgeusia, gallbladder disease, oral paresthesia, pancreatitis, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast secretion, breast swelling, change in cervical ectropion, change in cervical secretions, endometrial carcinoma (Altaras 1990), endometrial hyperplasia, malignant neoplasm of breast, nipple discharge, ovarian carcinoma, ovarian cyst, pelvic pain, uterine carcinoma, uterine fibroids, uterine hypertrophy, vaginal dryness, vaginitis, vulvar dryness, vulvovaginal pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage, purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, cholestatic jaundice, exacerbation of hepatic hemangioma</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, nonimmune anaphylaxis, swelling of lips, swollen tongue</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site burning, application-site pain, application-site rash, application-site vesicles, local inflammation (application site), localized edema (application site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, chorea, dementia, drowsiness, emotional disturbance, emotional lability, exacerbation of epilepsy, hemiparesis, hypoesthesia, insomnia, irritability, lethargy, malaise, mood disorder, nervousness, paresthesia, transient ischemic attacks, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, lower leg cramp, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blindness, blurred vision, contact lens intolerance, eye irritation, ocular hyperemia, retinal vein occlusion, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dry throat, dyspnea, exacerbation of asthma, pharyngeal edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Mass (breast)</p></div>
<div class="block coi drugH1Div" id="F8018348"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Angioedema, anaphylactic reaction, or hypersensitivity to estradiol or any component of the formulation; undiagnosed abnormal genital bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); breast cancer (known, suspected or history of), except in appropriately selected patients being treated for metastatic disease; estrogen-dependent tumor (known or suspected); hepatic impairment or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy (<b>Note:</b> Products approved for use only in patients who are postmenopausal are not appropriate for use in pregnancy; use of some products is specifically contraindicated in the manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): <b>Note:</b> May be dosage form dependent (consult product labeling): Breastfeeding; endometrial hyperplasia; active thrombophlebitis; partial or complete loss of vision or diplopia due to ophthalmic vascular disease; presence or history of hepatic tumors (benign or malignant); porphyria; classical migraine.</p></div>
<div class="block war drugH1Div" id="F8018349"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy. Angioedema involving the face, feet, hands, larynx, and tongue has also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Based on data from the Women’s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in patients who are postmenopausal using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA). Observational studies noted this risk declines once therapy is discontinued. The WHI study did not observe an increased risk of invasive breast cancer in patients with a hysterectomy using CE alone. The risk of breast cancer in patients who are postmenopausal receiving hormone therapy may depend upon type of estrogen and/or progestogen, dose, timing of therapy initiation, duration of therapy, route of administration, and individual patient characteristics (AACE/ACE [Cobin 2017]; NAMS 2022). Hormone therapy may be associated with increased breast density (NAMS 2022); an increase in abnormal mammogram findings requiring further evaluation has been reported with estrogen alone or in combination with progestogen therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Do not use estrogens with or without progestogen to prevent dementia. In the Women’s Health Initiative Memory Study (WHIMS), an increased incidence of probable dementia was observed in patients ≥65 years of age taking CE alone or in combination with MPA. Because the WHIMS was conducted in patients ≥65 years of age, it is unknown if these findings apply to younger patients who are postmenopausal. However, hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial cancer: The use of unopposed estrogen in patients with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestogen to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Perform adequate diagnostic measures, including endometrial sampling if indicated, to rule out malignancy in patients who are postmenopausal with undiagnosed abnormal vaginal bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer appears to be dose and duration dependent, greatest with use ≥5 years, and may persist following discontinuation of therapy. The use of a progestogen is not generally required when low doses of estrogen are used locally for vaginal atrophy, although long-term data (&gt;1 year) supporting this recommendation are lacking (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometriosis: Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestogen in patients with residual endometriosis posthysterectomy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased in patients with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: Available information related to the use of menopausal estrogen or estrogen/progestogen therapy and risk of ovarian cancer is inconsistent. If an association is present, the absolute risk is likely rare and may be influenced by duration of therapy (ES [Stuenkel 2015]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use caution with asthma; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Do not use estrogens with or without progestogen to prevent cardiovascular disease. The WHI studies reported an increased risk of deep vein thrombosis (DVT) and stroke with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) with CE with MPA in patients who are postmenopausal and 50 to 79 years of age. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, systemic lupus erythematosus, obesity, tobacco use, and/or history of venous thromboembolism. Adverse cardiovascular events have also been reported in patients taking estrogens for prostate cancer. Manage risk factors appropriately; discontinue use immediately if adverse cardiovascular events occur or are suspected. Due to possible lower risk of thrombotic events, transdermal administration may be preferred for treating vasomotor symptoms of menopause in patients with risk factors for cardiovascular disease (AACE/ACE [Cobin 2017]; ACOG 556 2013; ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: May impair glucose tolerance; use caution in patients with diabetes mellitus. Prior to therapy, consider age, cardiovascular and metabolic risk factors in patients previously diagnosed with diabetes (AACE/ACE [Cobin 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use caution with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epilepsy: Use caution with epilepsy; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic hemangiomas: Use caution with hepatic hemangiomas; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in patients with hereditary angioedema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoparathyroidism: Use caution with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use caution with migraine; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use caution with porphyria; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• SLE: Use caution with SLE; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Prior to puberty, estrogens may cause premature closure of the epiphyses. Premature breast development, vaginal bleeding, and vaginal cornification may be induced in girls. Modification of the normal puberty process may occur in boys.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Whenever possible, discontinue estrogens at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chlorobutanol: Some products may contain chlorobutanol (a chloral derivative) as a preservative, which may be habit forming.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical gel: Absorption of the topical gel (Elestrin) is increased by application of sunscreen; do not apply sunscreen within close proximity of estradiol. Application of sunscreen after EstroGel decreases absorption of estradiol, while application of moisturizer lotion after EstroGel increases the absorption of estradiol; the effect of applying sunscreen or lotion prior to Estrogel has not been studied. Application of Divigel with sunscreen has not been evaluated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical spray: When sunscreen is applied ~1 hour prior to the topical spray (Evamist), no change in absorption was observed (estradiol absorption was decreased when sunscreen is applied 1 hour after Evamist).</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaginal ring: Use may not be appropriate in patients with narrow vagina, vaginal stenosis, vaginal infections, cervical prolapse, rectoceles, cystoceles, or other conditions that may increase the risk of vaginal irritation, ulceration, or increase the risk of expulsion. Remove ring in case of ulceration, erosion, or adherence to vaginal wall; do not reinsert until healing is complete. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of use: Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Genitourinary syndrome of menopause: Low-dose vaginal estrogen is preferred over systemic therapy for genitourinary syndrome of menopause in the absence of vasomotor symptoms due to increased efficacy and decreased systemic effects (eg, cardiovascular effects, cancer risk) (Crandall 2018; NAMS 2020; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis use: In patients with premature menopause, hormone therapy to prevent bone loss may be used unless otherwise contraindicated; reassess therapy when the average age of menopause is reached. It is also an appropriate bone-active therapy for patients with vasomotor symptoms who are &lt;60 years of age or within 10 years of menopause onset. Consider for patients at high risk of fractures who are not candidates for other osteoporosis therapies (ES [Eastell 2019]; NAMS 2021; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Risks vs benefits: When used for the relief of menopausal symptoms or increased risk of bone fracture/loss, the benefit-risk of hormone therapy is most favorable if started in patients who have no contraindications to therapy, are &lt;60 years of age, within 10 years of menopause onset, have a favorable lipid profile, and do not have the factor V Leiden genotype or metabolic syndrome. Consider cardiovascular disease risk factors when evaluating therapy and route of administration (AACE/ACE [Cobin 2017]; NAMS 2022). Use for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual patient. Reevaluate patients as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from WHI studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in patients who were postmenopausal. Other combinations and dosage forms of estrogens and progestogens were not studied. Assume outcomes reported from clinical trials using CE with or without MPA to be similar for other doses and other dosage forms of estrogens and progestogens until comparable data becomes available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary exposure: Following application of the topical gel or mist, estradiol may be transferred to another person following skin-to-skin contact with the application site. Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional contact with application sites of patients using topical estradiol (Evamist). Instruct patients to strictly adhere to instructions for use in order to prevent secondary exposure. In most cases, conditions resolved with removal of estradiol exposure. If unexpected changes in sexual development occur in prepubertal children, evaluate the possibility of unintentional estradiol exposure. Discontinue if conditions for safe use cannot be met.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878734"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>
<div class="block foc drugH1Div" id="F8018425"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Divigel: 0.25 mg/0.25 g (30 ea); 0.5 mg/0.5 g (30 ea); 0.75 mg/0.75 g (30 ea); 1 mg/g (1 g); 1.25 mg/1.25 g (1.25 g) [contains propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elestrin: 0.06% (26 g) [contains edetate (edta) disodium, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estrogel: 0.06% (50 g) [contains alcohol, usp, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/0.25 g (1 ea, 30 ea); 0.5 mg/0.5 g (1 ea, 30 ea); 0.75 mg/0.75 g (1 ea, 30 ea); 1 mg/g (1 g); 1.25 mg/1.25 g (1.25 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oil, Intramuscular, as cypionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Estradiol: 5 mg/mL (5 mL) [contains chlorobutanol (chlorobutol)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oil, Intramuscular, as valerate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Delestrogen: 10 mg/mL (5 mL) [contains chlorobutanol (chlorobutol), sesame oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Delestrogen: 20 mg/mL (5 mL); 40 mg/mL (5 mL) [contains benzyl alcohol, benzyl benzoate, castor oil (ricine oil)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL); 20 mg/mL (5 mL); 40 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Twice Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alora: 0.025 mg/24 hr (1 ea, 8 ea [DSC]); 0.05 mg/24 hr (1 ea [DSC], 8 ea [DSC]); 0.075 mg/24 hr (1 ea, 8 ea [DSC]); 0.1 mg/24 hr (1 ea, 8 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dotti: 0.025 mg/24 hr (1 ea, 8 ea); 0.0375 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyllana: 0.025 mg/24 hr (1 ea, 8 ea); 0.0375 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minivelle: 0.025 mg/24 hr (1 ea, 8 ea); 0.0375 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vivelle-Dot: 0.025 mg/24 hr (1 ea, 8 ea); 0.0375 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025 mg/24 hr (1 ea, 8 ea); 0.0375 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Climara: 0.025 mg/24 hr (1 ea, 4 ea); 0.0375 mg/24 hr (1 ea, 4 ea); 0.05 mg/24 hr (1 ea, 4 ea); 0.06 mg/24 hr (1 ea, 4 ea); 0.075 mg/24 hr (1 ea, 4 ea); 0.1 mg/24 hr (1 ea, 4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Menostar: 14 mcg/24 hr (4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025 mg/24 hr (1 ea, 4 ea); 0.0375 mg/24 hr (1 ea, 4 ea); 0.05 mg/24 hr (1 ea, 4 ea); 0.06 mg/24 hr (1 ea, 4 ea); 0.075 mg/24 hr (1 ea, 4 ea); 0.1 mg/24 hr (1 ea, 4 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ring, Vaginal, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Femring: 0.05 mg/24 hr (1 ea); 0.1 mg/24 hr (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evamist: 1.53 mg/spray (8.1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estrace: 0.5 mg, 1 mg, 2 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block geq drugH1Div" id="F8018341"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8018427"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Divigel Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/0.25gm (per each): $6.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/0.5 g (per each): $6.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75MG/0.75GM (per each): $6.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/g (per gram): $6.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 mg/1.25 g (per gram): $5.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Elestrin Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.52 MG/0.87 GM (0.06%) (per gram): $5.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Estradiol Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/0.25gm (per each): $6.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/0.5 g (per each): $6.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75MG/0.75GM (per each): $6.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/g (per gram): $6.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 mg/1.25 g (per gram): $5.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Estrogel Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75 MG/1.25 GM (0.06%) (per gram): $3.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Oil</b> (Delestrogen Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $31.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $44.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $74.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Oil</b> (Depo-Estradiol Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $44.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Oil</b> (Estradiol Valerate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $28.64 - $29.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $33.38 - $40.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $55.37 - $66.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Climara Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $22.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.0375 mg/24 hrs (per each): $22.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $22.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.06 mg/24 hrs (per each): $22.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $22.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $22.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Estradiol Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $23.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.0375 mg/24 hrs (per each): $23.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $23.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.06 mg/24 hrs (per each): $23.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $23.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $23.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Menostar Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">14 mcg/24 hrs (per each): $48.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Alora Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $15.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $17.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $17.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Dotti Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $17.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.0375 mg/24 hrs (per each): $17.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $18.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $18.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $18.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Estradiol Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $11.33 - $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.0375 mg/24 hrs (per each): $11.34 - $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $11.34 - $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $11.35 - $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $11.35 - $24.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Lyllana Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.0375 mg/24 hrs (per each): $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $24.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $24.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Minivelle Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $34.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.0375 mg/24 hrs (per each): $34.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $34.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $34.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $34.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Vivelle-Dot Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025 mg/24 hrs (per each): $21.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.0375 mg/24 hrs (per each): $21.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $21.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.075 mg/24 hrs (per each): $22.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $22.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ring</b> (Femring Vaginal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/24 hrs (per each): $913.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $973.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Evamist Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.53 mg/spray (per mL): $20.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Estrace Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $6.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $6.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $8.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Estradiol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.55 - $1.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.68 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.94 - $3.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869135"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Divigel: 0.25 mg/0.25 g (1 ea); 0.5 mg/0.5 g (1 ea); 1 mg/g (1 ea, 1 g) [contains propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estrogel: 0.06% (80 g) [contains alcohol, usp, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Twice Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estradot 25: 0.025 mg/24 hr (8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estradot 37.5: 0.0375 mg/24 hr (8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estradot 50: 0.05 mg/24 hr (8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estradot 75: 0.075 mg/24 hr (8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estradot 100: 0.1 mg/24 hr (8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oesclim: 0.025 mg/24 hr (8 ea); 0.05 mg/24 hr (8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05 mg/24 hr (1 ea); 0.075 mg/24 hr (1 ea); 0.1 mg/24 hr (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Climara 25: 0.025 mg/24 hr (4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Climara 50: 0.05 mg/24 hr (4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Climara 75: 0.075 mg/24 hr (4 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block admp drugH1Div" id="F52614341"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food or after a meal to reduce GI upset</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Injection for IM use only</p>
<p style="text-indent:-2em;margin-left:4em;">Cypionate: Inspect for any particulate (particularly crystals); warming and shaking the vial should redissolve any crystals</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: <b>Note:</b> See package insert for administration related to postmenopausal symptoms, prevention of osteoporosis in postmenopausal women, and palliative treatment of breast cancer or androgen-dependent prostate cancer in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Gel (Divigel): Apply to clean, dry, unbroken skin at the same time each day. Apply entire contents of packet to right or left upper thigh each day (alternate sites). Do not apply to face, breasts, vaginal area, or irritated skin. Apply over an area ~5x7 inches. Do not wash application site for 1 hour. Allow to dry for 5 minutes prior to dressing. Gel is flammable; avoid fire or flame until dry. After application, wash hands with soap and water. Prior to the first use, pump must be primed.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch: Do not apply transdermal system to breasts, but place on trunk of body (preferably abdomen). Rotate application sites allowing a 1-week interval between applications at a particular site. Do not apply to oily, damaged or irritated skin; avoid waistline or other areas where tight clothing may rub the patch off. Apply patch immediately after removing from protective pouch. In general, if patch falls off, the same patch may be reapplied or a new system may be used for the remainder of the dosing interval (not recommended with all products) When replacing patch, reapply to a new site. Swimming, bathing, or showering are not expected to affect use of the patch. Note the following exceptions:</p>
<p style="text-indent:-2em;margin-left:6em;">Climara, Menostar, Minivelle: Swimming, bathing, or wearing patch while in a sauna have not been studied; adhesion of patch may be decreased or delivery of estradiol may be affected. Showering is not expected to cause the Minivelle patch to fall off. Remove patch slowly after use to avoid skin irritation. If any adhesive remains on the skin after removal, first allow skin to dry for 15 minutes, then gently rub area with an oil-based cream or lotion. If patch falls off, a new patch should be applied for the remainder of the dosing interval.</p></div>
<div class="block adm drugH1Div" id="F8018398"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Consider the use of a progestogen when administering estrogens to patients who are postmenopausal with a uterus.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection formulation:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Estradiol cypionate: Shake or gently warm vial to redissolve crystals that may have formed during storage.</p>
<p style="text-indent:-2em;margin-left:6em;">Estradiol valerate: Inject into the upper outer quadrant of the gluteal muscle; administer with a dry needle (solution may become cloudy with wet needle).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (off-label route):</b> Estradiol cypionate or estradiol valerate: When used for gender-affirming hormone therapy, administer into the thigh or abdomen; pause for 5 seconds with plunger depressed prior to removing needle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36868378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36868378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Gel: Apply to clean, dry, unbroken skin at the same time each day. Wash hands after application. Gel is flammable; avoid fire or flame until skin is dry. Avoid secondary exposure (eg, to children) by preventing unintentional contact with the application site.</p>
<p style="text-indent:-2em;margin-left:4em;">Divigel: Apply the entire contents of packet to right or left upper thigh each day (alternate sites) over a ~5 x 7-inch area. Do not apply to face, breasts, vaginal area, or irritated skin. Do not wash application site for 1 hour. Allow gel to dry before dressing.</p>
<p style="text-indent:-2em;margin-left:4em;">Elestrin: Apply the entire dose to upper arm and shoulder area using 2 fingers to spread gel. Do not apply to breasts or vaginal area. Allow skin to dry for ≥5 minutes prior to dressing. Prior to first use, pump must be primed. After priming, the pump contains 30 metered doses; discard pump after 30 doses even though container may not be empty. If &gt;1 dose is needed, wait 5 seconds before pumping next dose. To avoid secondary exposure, do not allow others to contact the application site for 2 hours after gel is applied. Allow at least 2 hours between applying gel and going swimming. Wait at least 25 minutes before applying sunscreen to application area. When sunscreen and gel are applied to the same site for &gt;7 consecutive days, the absorption of estradiol is increased; do not apply sunscreen to an area where the gel was applied for ≥7 consecutive days.</p>
<p style="text-indent:-2em;margin-left:4em;">EstroGel: Apply dose into the palm of hand and then apply gel to the other arm, from the wrist to the shoulder. Do not apply to breasts or vaginal area. Spread gel as thinly as possible over one arm but do not massage or rub in gel. Allow skin to dry for 5 minutes before dressing. Prior to first use, pump must be primed. After priming, the pump contains 32 daily doses (50 g canister) or 14 daily doses (25 g canister). Discard pump after allotted doses even though container may not be empty. To avoid secondary exposure, do not allow others to contact the application site for ≥1 hour after gel is applied. Wait as long as possible between applying gel and going swimming. When sunscreen was applied 1 hour after the gel to the same site for &gt;7 consecutive days, the absorption of estradiol was decreased; when moisturizing lotion was applied 1 hour after the gel to the same site for &gt;7 consecutive days, the absorption of estradiol was increased. The effect of applying sunscreen or lotion prior to the gel has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">Spray: Evamist: Prior to first use, prime pump by spraying 3 sprays with the cover on. To administer dose, hold container upright and vertical and rest the plastic cone flat against the skin while spraying. Spray to the inner surface of the forearm, starting near the elbow. If more than one spray is needed, apply to adjacent but not overlapping areas. Apply at the same time each day. Allow spray to dry for ~2 minutes; do not rub into skin; do not cover with clothing until dry. Do not wash application site for at least 60 minutes. Apply to clean, dry, unbroken skin. Do not apply to skin other than that of the forearm. Make sure that children do not come in contact with any skin area where the drug was applied. If contact with children is unavoidable, wear a garment with long sleeves that covers the site of application. If direct exposure occurs, wash the child in the area of exposure with soap and water as soon as possible. Solution contained in the spray is flammable; avoid fire, flame, or smoking until spray has dried. If needed, apply sunscreen ~1 hour prior to application of Evamist.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch: General administration instructions (also refer to product labeling): Apply patch immediately after removing from protective pouch to lower abdomen or buttocks. Apply to clean, dry, healthy skin that is free of oil, powder, or lotion. Avoid waistline or other areas where tight clothing may rub the patch off; do not apply to breasts. After application, hold patch in place using palm of hand for 10 seconds. Rotate application sites allowing a 1-week interval between applications at a particular site. In general, if patch falls off, the same patch may be reapplied or a new system may be used for the remainder of the dosing interval. When replacing patch, reapply to a new site. Remove patch slowly after use to avoid skin irritation. If any adhesive remains on the skin after removal, first allow skin to dry for 15 minutes, then gently rub area with an oil-based cream or lotion. Dispose of any used or unused patches by folding adhesive ends together, replace in pouch or sealed container, and discard properly in trash away from children and pets.</p>
<p style="text-indent:-2em;margin-left:4em;">Climara, Menostar: Swimming, bathing, or wearing patch while in a sauna have not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">Vaginal ring: Exact positioning is not critical for efficacy; however, patient should not feel anything once inserted. In case of discomfort, push ring further into vagina. If ring is expelled prior to 90 days, it may be rinsed off with warm water and reinserted. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion. Femring may remain in place during local treatment of a vaginal infection. Femring may remain in place during sexual intercourse; however, if it is removed or expelled, it may be rinsed off with warm water and reinserted.</p></div>
<div class="block hazard drugH1Div" id="F49132514"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F12764945"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store all products at room temperature. In addition:</p>
<p style="text-indent:-2em;margin-left:4em;">Depo-Estradiol: Protect from light.</p>
<p style="text-indent:-2em;margin-left:4em;">Evamist: Do not freeze. Discard any unused portion once 56 sprays after priming are used.</p>
<p style="text-indent:-2em;margin-left:4em;">Femring: Store in pouch. Storage excursions permitted to −20°C to 40°C (−4°F to 104°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch (all products): Store in protective pouch.</p>
<p style="text-indent:-2em;margin-left:4em;">Climara, Menostar: Do not store &gt;30°C (&gt;86°F).</p></div>
<div class="block usep drugH1Div" id="F53570494"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; treatment of moderate to severe vasomotor symptoms of menopause, moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, palliative treatment of breast cancer in select patients, palliative treatment of androgen-dependent prostate cancer, and prevention of osteoporosis in postmenopausal women (All indications: FDA approved in adults); has also been used for management of Turner Syndrome and for induction of puberty in patients with delayed puberty </p></div>
<div class="block mst drugH1Div" id="F8018336"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Alora may be confused with Aldara</p>
<p style="text-indent:-2em;margin-left:4em;">Elestrin may be confused with alosetron</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappropriate medications to be avoided in postmenopausal patients ≥65 years of age (independent of diagnosis or condition) due to their carcinogenic potential (breast and endometrium) and lack of cardioprotection or cognitive protection. Starting therapy in postmenopausal patients ≥60 years of age has greater risks (eg, heart disease, stroke, blood clots, dementia) than benefits. In postmenopausal patients already taking systemic estrogens, consider deprescribing (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vivelle: Brand name for estradiol [US and multiple international markets, but also the brand name for ethinyl estradiol and norgestimate [Austria]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8018356"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F8018357"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Estrogen Derivatives. Protease Inhibitors may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Estrogen Derivatives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F8018361"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Folic acid absorption may be decreased.</p></div>
<div class="block dic drugH1Div" id="F8018397"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.</p></div>
<div class="block rep_considerations drugH1Div" id="F57053101"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Estradiol is a component of therapy for transgender females (assigned male at birth). Gender-affirming hormone therapy may cause subfertility or infertility. Consider options for preserving fertility prior to therapy (ACOG 2021; Ellis 2019; ES [Hembree 2017]; WPATH [Coleman 2022]); however, gender-affirming hormone therapy should not be considered effective contraception; sexually active patients should consider the possibility of pregnancy and use contraception if pregnancy is not desired (ACOG 2021; WPATH [Coleman 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">When treating patients with secondary amenorrhea (hypoestrogenism) due to primary ovarian failure, consider barrier methods of contraception or use of an IUD in patients not wishing to become pregnant (ACOG 2017).</p></div>
<div class="block pri drugH1Div" id="F8018344"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Products approved for use only in patients who are postmenopausal are not appropriate for use during pregnancy; use of some products is specifically contraindicated in the manufacturer's labeling.</p>
<p style="text-indent:0em;margin-top:2em;">In general, the use of estrogen and progestogen as in combination hormonal contraceptives has not been associated with teratogenic effects when inadvertently taken early in pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53570493"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, weight, height, serum calcium, glucose, liver enzymes; bone maturation and epiphyseal effects in young patients in whom bone growth is not complete; breast exam, mammogram, Papanicolaou smear, signs for endometrial cancer in female patients with a uterus; bone density measurement if used for prevention of osteoporosis</p>
<p style="text-indent:0em;margin-top:2em;">Turner Syndrome and CDPG (puberty induction): Adolescents: Signs of puberty progression, ovarian tissue growth/changes (pelvic ultrasound), height, weight, growth parameters, breast exam, mammogram, Papanicolaou smear (Sperling 2014)</p></div>
<div class="block rerp drugH1Div" id="F53569971"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients (Janfaza 2006):</p>
<p style="text-indent:-2em;margin-left:4em;">Tanner stage 1: Females: 5.9 ± 9.7 pmol/L, Males: 1.5 ± 4.1</p>
<p style="text-indent:-2em;margin-left:4em;">Tanner stage 2: Females: 25.3 ± 4.0 pmol/L, Males: 2.6 ± 3.0</p>
<p style="text-indent:-2em;margin-left:4em;">Tanner stage 3: Females: 84.1 ± 120.5 pmol/L, Males: 8.7 ± 11.0</p>
<p style="text-indent:-2em;margin-left:4em;">Tanner stage 4: Females: 97.3 ± 137.7 pmol/L, Males: 13.0 ± 9.4</p>
<p style="text-indent:-2em;margin-left:4em;">Tanner stage 5: Females: 174.3 ± 239.5 pmol/L, Males: 15.5 ± 9.4</p>
<p style="text-indent:-2em;margin-left:2em;">Adults: </p>
<p style="text-indent:-2em;margin-left:4em;">Females: </p>
<p style="text-indent:-2em;margin-left:6em;">Premenopausal: 30 to 400 pg/mL (SI: 110 to 1,468 pmol/L) (depending on phase of menstrual cycle)</p>
<p style="text-indent:-2em;margin-left:6em;">Postmenopausal: 0 to 30 pg/mL (SI: 0 to 110 pmol/L)</p>
<p style="text-indent:-2em;margin-left:4em;">Adult males: 10 to 50 pg/mL (SI: 37 to 184 pmol/L) </p></div>
<div class="block pha drugH1Div" id="F8018378"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in patients who are postmenopausal.</p></div>
<div class="block phk drugH1Div" id="F8018385"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed from the gastrointestinal tract, mucous membranes, and the skin. Average serum estradiol concentrations (C<sub>avg</sub>) vary by product</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Estradiol valerate and estradiol cypionate are absorbed over several weeks following IM injection</p>
<p style="text-indent:-2em;margin-left:4em;">Topical:</p>
<p style="text-indent:-2em;margin-left:6em;">Alora: C<sub>avg</sub>: 41 to 98 pg/mL</p>
<p style="text-indent:-2em;margin-left:6em;">Climara: C<sub>avg</sub>: 22 to 106 pg/mL</p>
<p style="text-indent:-2em;margin-left:6em;">Divigel: C<sub>avg</sub>: 9.8 to 30.5 pg/mL</p>
<p style="text-indent:-2em;margin-left:6em;">Elestrin: C<sub>avg</sub>: 15.4 to 39.2 pg/mL; Exposure increased by 55% with application of sunscreen 10 minutes prior to dose</p>
<p style="text-indent:-2em;margin-left:6em;">Estrogel: C<sub>avg</sub> on day 14 of therapy: 28.3 pg/mL. C<sub>max</sub> of estradiol is altered by repeated daily application (for 7 days) of sunscreen (decreased by 16%) or lotion (increased by 73%) when applied 1 hour after the dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Evamist: C<sub>avg</sub>: 19.6 to 30.9 pg/mL</p>
<p style="text-indent:-2em;margin-left:6em;">Menostar: C<sub>avg</sub>: 13.7 pg/mL</p>
<p style="text-indent:-2em;margin-left:6em;">Vivelle-Dot: C<sub>avg</sub>: 34 to 104 pg/mL</p>
<p style="text-indent:-2em;margin-left:4em;">Vaginal: Femring: Rapid during the first hour following application, then declines to a steady rate over 3 months; C<sub>avg</sub>: 40.6 to 76 pg/mL</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed; high concentrations in the sex hormone target organs</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Bound to sex hormone-binding globulin and albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in patients who are postmenopausal. With transdermal application, less estradiol is metabolized leading to higher circulating concentrations of estradiol and lower concentrations of estrone and conjugates.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (as estradiol, estrone, estriol and their glucuronide and sulfate conjugates)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390228"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Estraderm | Progynon | Progynon B</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Climaderm 7 Dias | Estraderm | Estraderm mx | Estradot | Estreva | Evorel | Ginatex | Lindisc | Progynon | Replasyn | Rontagel | Transdiol | Trial | Trial sat | Trial sat l.a</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Climara | Cycloderm | Dermestril septem | Estraderm | Estraderm mx | Estradot matrix | Estramon | Estrogel | Femseven | Menorest | Systen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Estraderm | Estradot | Estrogel | Femtran | Menorest | Primogyn | Sandrena</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Estraderm</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Benzo gynoestryl | Climara | Dermestril | Estraderm | Estradiol Hexal | Estreva | Feminova | Oestrogel | Systen | Vivelle dot</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Oestrogel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Estraderm | Oestrogel | Systen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Benzo Ginoestril | Climaderm 7 Dias | Estraderm | Estraderm Matrix | Estradot | Estrelle | Estreva | Fem 7 | Ginedisc | Hormodose | Lindisc | Menorest | Oestrogel | Sandrena | Systen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cerina | Climara | Divigel | Estraderm | Estraderm mx | Estradot | Oestrogel | Sandrena | Systen | Systen 100</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Climaderm | Dermatrans | Epiestrol | Estreva | Fem 7 | Femiderm | Ginoderm | Hormogel | Hormogel pump | Oesclim | Primofol | Sandrena | Transvital</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Fem7 | Oesclim | Oestrogel</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Climaderm 7 Dias | Divigel | Estraderm | Estraderm Matrix | Estreva | Estrogel | Fem 7 | Ginedisc | Ginoderm | Lindisc | Menodin | Menodin tts | Menorest | Progynon | Systen Stt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Divigel | Estraderm | Estraderm mx | Estrahexal | Estreva | Fem 7 | Neofollin | Oestrogel | Systen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aerodiol | Cutanum | Dermestril | Ephelia | Estrabeta | Estraderm | Estradot | Estramon uno | Estreva | Fem7 | Femsept | Gynokadin | Gynpolar | Menorest | Mopraxon | Sandrena | Sisare mono | Tradelia</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Climaderm 7 Dias | Estocrema | Estraderm | Estrocrema | Estrogel | Evorel | Fem 7</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Climaderm 7 Dias | Estraderm | Estraderm Matrix | Estreva | Estrogel | Ginoderm | Lindisc | Menodin | Primogyn</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Climara | Climara forte | Dermestril | Divigel | Estraderm | Estradot | Estramon | Estrogel | Menorest | Oesclim | Systen-50</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Estraderm | Estraderm mx | Folone | Primogyn</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Absorlent matrix | Alcis | Alcis semanal | Cliogan | Dermestril | Dermestril septem | Endomina | Estraderm Matrix | Estradiol bexal | Estradot | Estroffik | Evopad | Menorest | Oestraclin | Progynova</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dermestril | Dermestril septem | Divigel | Estraderm | Estraderm Matrix | Estradot | Estrena | Estrogel | Evorel | Femseven | Menorest | Ovocyclin m | Primogyn</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Climara | Delidose | Dermestril | Dermestril septem | Estraderm | Estradiol g gam | Estrapatch | Estreva | Evafilm | Femsept | Menorest | Oesclim | Oestrodose | Oestrogel | Thais | Thais sept | Vivelledot</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Benztrone | Dermestril | Estraderm | Estraderm mx | Estradot | Evorel | Fematrix | Femseven | Menorest | Oestradiol | Oestrogel | Primogyn | Progynova ts | Sandrena</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dermestril | Estraderm | Estramon | Menorest | Oestrogel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dermestril | Estraderm | Estramon | Estreva | Oestrogel</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Estradot</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dermestril | Divigel | Estraderm | Estraderm mx | Estramon | Estrapatch | Oesclim | Oestrogel | Systen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Estraderm | Estreva | Femseven | Oestradiol Benzoas | Oestrogel | Progynon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Climara | Divigel | Epiestrol | Estraderm | Estraderm mx | Estradot | Estramon | Evorel | Fematrix | Femseven | Menorest | Oestrogel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Estraderm | Evorel | Oestrodose | Oestrogel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Divigel | E2 | Estofert tg | Estogel | Estogen | Estraderm | Estraderm mx | Ets | Oesclim | Oestrogel | Progynon | Prostium e | Sandrena | Systen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Armonil | Armonil septem | Climara | Dermestril | Dermestril septem | Ephelia | Epiestrol | Esclima | Estraderm | Estraderm mx | Estradiolo amsa | Estradiolo angelin | Estreva | Estroclim | Estroclim mx | Estrodose | Femseven | Gelestra | Ginaikos | Menorest | Progynon | Sandrena | Systen | Zerella</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Estraderm</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dep estiol | Depo Estradiol | Divigel | Estohormon | Estormon | Estraderm | Estraderm kissei | Estradiol f | Estrana | Femiest | Femiest teizo | Femiest yakult | L'estrogel | Ovahormon | Pelanin dep | Progynon | Progynon dep</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Oestrogel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betadiol | Climara | Depo Estradiol | Depofemin | Dermestril | Divigel | Est | Estraderm | Estraderm mx | Estradiol deport | Estran 50 | Estreva | Estrodose | Miro-depo f | Oestrodose</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Estraderm</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Estraderm | Estreva | Oesclim | Oestraclin | Oestrodose | Oestrogel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Climara | Divigel | Estraderm | Estradot | Estramon | Estreva | Estrogel | Neofollin | Oesclim | Oestradiol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Dimenformon | Estraderm | Estraderm Matrix | Estraderm mx | Estramon | Estreva | Fem 7 | Oestrogel</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Agofollin | Climara | Dermestril | Divigel | Estraderm | Estraderm mx | Estradot | Estramon | Estreva | Estrogel | Neofollin | Oesclim | Oestradiol | Oestrogel | Sisare mono</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Estraderm | Estraderm mx | Estrapatch | Estreva | Oestrodose | Oestrogel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Benzo ginestryl | Climaderm | Essventia | Estraderm | Estraderm dot | Estraderm mtx | Estradiol antibioticos | Estramon | Estreva | Evorel | Fem-7 | Ginedisc | Oestrogel | Primogyn | Sandrena | Systen Stt</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Divigel | Oestrogel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Estraderm | Estraderm Matrix | Estradiol once weekly | Estradiol sandoz | Estradot | Fem 7 | Menorest | Oestrogel | Sandrena | Systen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Divigel | Estraderm | Estraderm Matrix | Estradot | Estramon | Estrogel | Evorel | Menorest | Vivelle dot</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Climara | Estraderm | Estraderm mx | Estradot | Femtran | Oestrogel | Sandrena</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Estraderm | Estraderm mx | Estreva | Estrogel | Fem 7 | Ginedisc | Gynoderm | Lindisc | Oestraclin | Progynon</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Climara | Estraderm mx | Oestrodose | Oestrogel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ovlogyn | Progynon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Climara | Delestrogen | Dermestril | Divigel | Estraderm | Estraderm mx | Estradot | Estrapatch | Estreva | Estrium | Estroplast | Fem 7 | Neofollin | Oesclim | Oestradiol | Oestradiolum benzoicum | Oestrogel | Systen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alora | Climara | Delestrogen | Depo Estradiol | Divigel | Dotti | Esclim | Estraderm | Estradiol transdermal | Estradiol transdermal system | Estrogel | Lyllana | Menostar | Minivelle | Vivelle | Vivelle dot</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Estraderm mx | Estradot | Estreva | Estronar | Estronar Gel | Femsete | Menorest</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ginoderm</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Estraderm | Estreva | Fem 7 | Oestrogel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Climara | Divigel | Estrogel | Oestrogel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Estraderm</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Estradot | Estrogel | Evorel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Divigel | Estraderm mx | Estreva | Fem7 | Oestrogel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Climara | Estraderm | Fem 7 | Oestrogel</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Climara | Dermestril | Divigel | Estraderm | Estraderm mx | Estrahexal | Estreva | Fem 7 | Neofollin | Oestrogel | Systen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Climara | Depo Estradiol | Divigel | Estraderm | Ginoderm | Oestradiol Benzoate March | Oestrodose | Oestrogel | Progynon</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dermestril | Estraderm | Estreva | Oestrodose | Oestrogel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Akrofolline | Climara | Estraderm | Estreva | Femijel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Climara | Depot-hormon-f | Divigel | Eburol | Eremon | Estamon | Estolmon | Estra | Estrad | Estraderm | Estraderm mx | Estradiol | Estradiol cypionate | Estramon | Gele | Hormin | Hormon-f | Ladiol | Nismon | Oestrogel | Ultradiol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Divigel | Estraderm | Estramon | Oestrogel</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Climaderm 7 Dias | Estraderm | Estradot | Evorel | Gadogel | Ginatex | Ginedisc | Lindisc | Oestrogel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Climaderm | Estraderm | Estraderm Matrix | Estradot | Estrogel | Femseven | Ginedisc | Ginoderm | Systen Stt</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Climara | Estraderm | Estradot | Evorel | Femigel | Primogyn</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Femigel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34153174">
<a name="34153174"></a>Aapkes SE, Bernts LHP, Barten TRM, van den Berg M, Gansevoort RT, Drenth JPH. Estrogens in polycystic liver disease: a target for future therapies? <i>Liver Int.</i> 2021;41(9):2009-2019. doi:10.1111/liv.14986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/34153174/pubmed" id="34153174" target="_blank">34153174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32450447">
<a name="32450447"></a>Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. <i>Thromb Res</i>. 2020;192:40-51. doi:10.1016/j.thromres.2020.05.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/32450447/pubmed" id="32450447" target="_blank">32450447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30301734">
<a name="30301734"></a>Ackerman KE, Singhal V, Baskaran C, et al. Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. <i>Br J Sports Med.</i> 2019;53(4):229-236. doi:10.1136/bjsports-2018-099723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/30301734/pubmed" id="30301734" target="_blank">30301734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31603998">
<a name="31603998"></a>Ackerman KE, Singhal V, Slattery M, et al. Effects of estrogen replacement on bone geometry and microarchitecture in adolescent and young adult oligoamenorrheic athletes: a randomized trial. <i>J Bone Miner Res.</i> 2020;35(2):248-260. doi:10.1002/jbmr.3887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/31603998/pubmed" id="31603998" target="_blank">31603998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.1">
<a name="Allergan.1"></a>Alora (estradiol transdermal system) [prescribing information]. Madison, NJ: Allergan USA, Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2167285">
<a name="2167285"></a>Altaras MM, Jaffe R, Cohen I, Gruber A, Yanai-Inbar I, Bernheim J. Role of prolonged excessive estrogen stimulation in the pathogenesis of endometrial sarcomas: two cases and a review of the literature. <i>Gynecol Oncol</i>. 1990;38(2):273-277. doi: \10.1016/0090-8258(90)90054-o<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/2167285/pubmed" id="2167285" target="_blank">2167285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635705">
<a name="23635705"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. <i>Obstet Gynecol</i>. 2013;121:887-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/23635705/pubmed" id="23635705" target="_blank">23635705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812486">
<a name="23812486"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 565: Hormone therapy and heart disease. <i>Obstet Gynecol</i>. 2013;121:1407-1410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/23812486/pubmed" id="23812486" target="_blank">23812486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28426619">
<a name="28426619"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 698: Hormone therapy in primary ovarian insufficiency. <i>Obstet Gynecol.</i> 2017;129(5):e134-e141. doi:10.1097/AOG.0000000000002044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28426619/pubmed" id="28426619" target="_blank">28426619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24463691">
<a name="24463691"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: management of menopausal symptoms. <i>Obstet Gynecol</i>. 2014;123(1):202-216. doi: 10.1097/01.AOG.0000441353.20693.78. Erratum in: <i>Obstet Gynecol.</i> 2016;127(1):166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/24463691/pubmed" id="24463691" target="_blank">24463691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33595253">
<a name="33595253"></a>American College of Obstetricians and Gynecologists. Health care for transgender and gender diverse individuals: ACOG committee opinion, number 823.<i> Obstet Gynecol</i>. 2021;137(3):e75-e88. doi:10.1097/AOG.0000000000004294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/33595253/pubmed" id="33595253" target="_blank">33595253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22401913">
<a name="22401913"></a>Anderson GL, Chlebowski RT, Aragaki AK, et al, "Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial," <i>Lancet Oncol,</i> 2012,13(5):476-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/22401913/pubmed" id="22401913" target="_blank">22401913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15082697">
<a name="15082697"></a>Anderson GL, Limacher M, Assaf AR, et al, "Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial." <i>JAMA</i>, 2004, 291(14):1701-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/15082697/pubmed" id="15082697" target="_blank">15082697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11443165">
<a name="11443165"></a>Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. <i>J Clin Endocrinol Metab</i>. 2001;86(7):3039-3044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/11443165/pubmed" id="11443165" target="_blank">11443165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19200215">
<a name="19200215"></a>Bannink EM, van Sassen C, van Buuren S, et al. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. <i>Clin Endocrinol (Oxf)</i>. 2009;70(2):265-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19200215/pubmed" id="19200215" target="_blank">19200215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399218">
<a name="25399218"></a>Bawazeer NA, Al-Jifree HM, Gari AM. Malignant transformation of persistent endometriosis after hysterectomy. <i>Saudi Med J</i>. 2014;35(11):1390-1392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/25399218/pubmed" id="25399218" target="_blank">25399218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17047017">
<a name="17047017"></a>Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. <i>J Clin Endocrinol Metab</i>. 2007;92(1):10-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/17047017/pubmed" id="17047017" target="_blank">17047017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34849527">
<a name="34849527"></a>Bortz J, Klatt KC, Wallace TC. Perspective: estrogen and the risk of cognitive decline: a missing choline(rgic) link? <i>Adv Nutr</i>. 2022;13(2):376-387. doi:10.1093/advances/nmab145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/34849527/pubmed" id="34849527" target="_blank">34849527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23680641">
<a name="23680641"></a>Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. <i>J Steroid Biochem Mol Biol</i>. 201l;142:83-89. doi:10.1016/j.jsbmb.2013.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/23680641/pubmed" id="23680641" target="_blank">23680641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196674">
<a name="19196674"></a>Chlebowski RT, Kuller LH, Prentice RL, et al, "Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women," <i>N Engl J Med</i>, 2009, 360(6):573-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19196674/pubmed" id="19196674" target="_blank">19196674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15657326">
<a name="15657326"></a>Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, LaCroix AZ, Limacher MC, Larson JC. Effect of estrogen therapy on gallbladder disease. <i>JAMA</i>. 2005;293(3):330-339. doi:10.1001/jama.293.3.330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/15657326/pubmed" id="15657326" target="_blank">15657326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bayer.1">
<a name="Bayer.1"></a>Climara (estradiol transdermal system) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bayer.2">
<a name="Bayer.2"></a>Climara 25, Climara 50, Climara 75 (estradiol hemihydrate transdermal system) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi: 10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36238954">
<a name="36238954"></a>Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. <i>Int J Transgend Health</i>. 2022;23(Suppl 1):S1-S259. doi:10.1080/26895269.2022.2100644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/36238954/pubmed" id="36238954" target="_blank">36238954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31474332">
<a name="31474332"></a>Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. <i>Lancet</i>. 2019;394(10204):1159-1168. doi:10.1016/S0140-6736(19)31709-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/31474332/pubmed" id="31474332" target="_blank">31474332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28816933">
<a name="28816933"></a>Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i>. 2018;25(1):11-20. doi: 10.1097/GME.0000000000000956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28816933/pubmed" id="28816933" target="_blank">28816933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17179984">
<a name="17179984"></a>Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. <i>Br J Cancer</i>. 2007;96(1):151-156. doi:10.1038/sj.bjc.6603527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/17179984/pubmed" id="17179984" target="_blank">17179984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20375216">
<a name="20375216"></a>Davenport ML. Approach to the patient with Turner syndrome. <i>J Clin Endocrinol Metab</i>. 2010;95(4):1487-1495.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/20375216/pubmed" id="20375216" target="_blank">20375216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24463911">
<a name="24463911"></a>De Souza MJ, Nattiv A, Joy E, et al; Expert Panel. 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad: 1st international conference held in San Francisco, California, May 2012 and 2nd international conference held in Indianapolis, Indiana, May 2013. <i>Br J Sports Med.</i> 2014;48(4):289. doi:10.1136/bjsports-2013-093218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/24463911/pubmed" id="24463911" target="_blank">24463911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Delestrogen (estradiol valerate) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pharmacia.1">
<a name="Pharmacia.1"></a>Depo-Estradiol (estradiol cypionate) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Company LLC; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20581664">
<a name="20581664"></a>DeSancho MT, Dorff T, and Rand JH, "Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy," <i>Blood Coagul Fibrinolysis</i>, 2010, 21(6):534-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/20581664/pubmed" id="20581664" target="_blank">20581664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vertical.1">
<a name="Vertical.1"></a>Divigel (estradiol gel) [prescribing information]. Alpharetta, GA; Vertical Pharmaceuticals LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Searchlight.1">
<a name="Searchlight.1"></a>Divigel (estradiol) gel [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34781041">
<a name="34781041"></a>Doll E, Gunsolus I, Thorgerson A, Tangpricha V, Lamberton N, Sarvaideo JL. Pharmacokinetics of sublingual versus oral estradiol in transgender women. <i>Endocr Pract</i>. 2022;28(3):237-242. doi:10.1016/j.eprac.2021.11.081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/34781041/pubmed" id="34781041" target="_blank">34781041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meda.1">
<a name="Meda.1"></a>Elestrin (estradiol) gel [prescribing information]. Canonsburg, PA: Meda Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19690310">
<a name="19690310"></a>Ellis MJ, Gao F, Dehdashti F, et al, “Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer: A Phase 2 Randomized Study,” <i>JAMA</i>, 2009, 302(7):774-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19690310/pubmed" id="19690310" target="_blank">19690310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30957961">
<a name="30957961"></a>Ellis SA, Dalke L. Midwifery care for transfeminine individuals. <i>J Midwifery Womens Health</i>. 2019;64(3):298-311. doi:10.1111/jmwh.12957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/30957961/pubmed" id="30957961" target="_blank">30957961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Warner.1">
<a name="Warner.1"></a>Estrace (estradiol) [prescribing information]. Rockaway, NJ: Warner Chilcott, LLC; April 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.2">
<a name="Allergan.2"></a>Estrace (estradiol) cream [prescribing information]. Madison, NJ: Allergan; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.3">
<a name="Allergan.3"></a>Estrace (estradiol) tablets [prescribing information]. Irvine, CA: Allergan USA Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Acerus.1">
<a name="Acerus.1"></a>Estrace (estradiol) tablets [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.1">
<a name="Novartis.1"></a>Estraderm (estradiol) [prescribing information]. East Hanover, PA: Novartis Pharmaceuticals; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.2">
<a name="Novartis.2"></a>Estradot (estradiol) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Medicis.2">
<a name="Medicis.2"></a>Estrasorb (estradiol topical emulsion) [prescribing information]. Scottsdale, AZ: Medicis; December 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DPT.1">
<a name="DPT.1"></a>EstroGel (estradiol gel) [prescribing information]. San Antonio, TX: DPT Laboratories Ltd; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Organon.2">
<a name="Organon.2"></a>EstroGel (estradiol as estradiol hemihydrate) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15339752">
<a name="15339752"></a>Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. <i>Obstet Gynecol</i>. 2004;104(3):443-451. doi:10.1097/01.AOG.0000137833.43248.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/15339752/pubmed" id="15339752" target="_blank">15339752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perrigo.2">
<a name="Perrigo.2"></a>Evamist (estradiol transdermal spray) [prescribing information]. Allegan, MI: Padagis; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Millicent.1">
<a name="Millicent.1"></a>Femring (estradiol acetate) [prescribing information]. East Hanover, NJ: Millicent US Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.4">
<a name="Allergan.4"></a>Femtrace (estradiol acetate) [prescribing information]. Irvine, CA: Allergan USA Inc; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33948625">
<a name="33948625"></a>Freier E, Kassel L, Rand J, Chinnakotla B. Estrogen-induced gallstone pancreatitis in a transgender female. <i>Am J Health Syst Pharm</i>. 2021;78(18):1674-1680. doi:10.1093/ajhp/zxab190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/33948625/pubmed" id="33948625" target="_blank">33948625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28498913">
<a name="28498913"></a>Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. <i>Hum Reprod Update</i>. 2017;23(4):481-500. doi:10.1093/humupd/dmx011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28498913/pubmed" id="28498913" target="_blank">28498913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987313">
<a name="29987313"></a>Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study.<i> Ann Intern Med</i>. 2018;169(4):205-213. doi:10.7326/M17-2785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/29987313/pubmed" id="29987313" target="_blank">29987313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34439184">
<a name="34439184"></a>Giannella L, Marconi C, Di Giuseppe J, et al. Malignant transformation of postmenopausal endometriosis: a systematic review of the literature. <i>Cancers (Basel)</i>. 2021;13(16):4026. doi:10.3390/cancers13164026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/34439184/pubmed" id="34439184" target="_blank">34439184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20019127">
<a name="20019127"></a>Gibbs RB. Estrogen therapy and cognition: a review of the cholinergic hypothesis. <i>Endocr Rev</i>. 2010;31(2):224-253. doi:10.1210/er.2009-0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/20019127/pubmed" id="20019127" target="_blank">20019127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31372078">
<a name="31372078"></a>Goldstein Z, Khan M, Reisman T, Safer JD. Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. <i>J Blood Med</i>. 2019;10:209-216. doi:10.2147/JBM.S166780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/31372078/pubmed" id="31372078" target="_blank">31372078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28368518">
<a name="28368518"></a>Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2017;102(5):1413-1439. doi: 10.1210/jc.2017-00131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28368518/pubmed" id="28368518" target="_blank">28368518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16278618">
<a name="16278618"></a>Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. <i>Menopause</i>. 2005;12(6):741-748. doi:10.1097/01.gme.0000184425.73567.12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/16278618/pubmed" id="16278618" target="_blank">16278618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320642">
<a name="29320642"></a>Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. <i>Endocr Pract</i>. 2017;23(12):1437. doi: 10.4158/1934-2403-23.12.1437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/29320642/pubmed" id="29320642" target="_blank">29320642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36868378">
<a name="36868378"></a>Herndon JS, Maheshwari AK, Nippoldt TB, Carlson SJ, Davidge-Pitts CJ, Chang AY. Comparison of the subcutaneous and intramuscular estradiol regimens as part of gender-affirming hormone therapy. <i>Endocr Pract</i>. 2023;29(5):356-361. doi:10.1016/j.eprac.2023.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/36868378/pubmed" id="36868378" target="_blank">36868378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19226267">
<a name="19226267"></a>Hindmarsh PC. How do you initiate oestrogen therapy in a girl who has not undergone puberty? <i>Clin Endocrinol (Oxf)</i>. 2009;71(1):7-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19226267/pubmed" id="19226267" target="_blank">19226267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16476878">
<a name="16476878"></a>Hsia J, Langer RD, Manson JE, et al, "Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative," <i>Arch Intern Med</i>, 2006, 166(3):357-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/16476878/pubmed" id="16476878" target="_blank">16476878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17620054">
<a name="17620054"></a>Huang AJ, Ettinger B, Vittinghoff E, Ensrud KE, Johnson KC, Cummings SR. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. <i>J Bone Miner Res</i>. 2007;22(11):1791-1797. doi:10.1359/jbmr.070707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/17620054/pubmed" id="17620054" target="_blank">17620054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9718051">
<a name="9718051"></a>Hulley S, Grady D, Bush T, et al, “Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,” <i>JAMA</i>, 1998, 280(7):605-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/9718051/pubmed" id="9718051" target="_blank">9718051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16995570">
<a name="16995570"></a>Janfaza M, Sherman TI, Larmore KA, Brown-Dawson J, Klein KO. Estradiol levels and secretory dynamics in normal girls and boys as determined by an ultrasensitive bioassay: a 10 year experience. <i>J Pediatr Endocrinol Metab</i>. 2006;19(7):901-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/16995570/pubmed" id="16995570" target="_blank">16995570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10818427">
<a name="10818427"></a>Kalantaridou SN, Nelson LM. Premature ovarian failure is not premature menopause. <i>Ann N Y Acad Sci.</i> 2000;900:393-402. doi:10.1111/j.1749-6632.2000.tb06251.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/10818427/pubmed" id="10818427" target="_blank">10818427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3358913">
<a name="3358913"></a>Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. <i>Br J Cancer</i>. 1988;57(2):205-212. doi:10.1038/bjc.1988.44<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/3358913/pubmed" id="3358913" target="_blank">3358913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30358726">
<a name="30358726"></a>Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. <i>Menopause</i>. 2018;25(11):1297-1305. doi:10.1097/GME.0000000000001232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/30358726/pubmed" id="30358726" target="_blank">30358726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27054934">
<a name="27054934"></a>Lee AW, Ness RB, Roman LD, et al. Association between menopausal estrogen-only therapy and ovarian carcinoma risk. <i>Obstet Gynecol</i>. 2016;127(5):828-836. doi:10.1097/AOG.0000000000001387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/27054934/pubmed" id="27054934" target="_blank">27054934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31849838">
<a name="31849838"></a>Liu Y, Ma L, Yang X, et al. Menopausal hormone replacement therapy and the risk of ovarian cancer: a meta-analysis. <i>Front Endocrinol (Lausanne)</i>. 2019;10:801. doi:10.3389/fendo.2019.00801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/31849838/pubmed" id="31849838" target="_blank">31849838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617493">
<a name="18617493"></a>Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. <i>BMJ</i>. 2008;337:a386. doi:10.1136/bmj.a386<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/18617493/pubmed" id="18617493" target="_blank">18617493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Martin.1">
<a name="Martin.1"></a>Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Martin.2">
<a name="Martin.2"></a>Martin KA, Barbieri RL. Preparations for menopausal hormone therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bayer.3">
<a name="Bayer.3"></a>Menostar (estradiol transdermal system) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Noven.1">
<a name="Noven.1"></a>Minivelle (estradiol transdermal system) [prescribing information]. Miami, FL: Noven Pharmaceuticals Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21698665">
<a name="21698665"></a>Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. <i>J Bone Miner Res</i>. 2011;26(10):2430-2438. doi:10.1002/jbmr.447.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/21698665/pubmed" id="21698665" target="_blank">21698665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19602689">
<a name="19602689"></a>Mørch LS, Løkkegaard E, Andreasen AH, et al, “Hormone Therapy and Ovarian Cancer,” <i>JAMA</i>, 2009, 302(3):298-305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19602689/pubmed" id="19602689" target="_blank">19602689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196677">
<a name="19196677"></a>Nelson LM. Clinical practice. Primary ovarian insufficiency.<i> N Engl J Med</i>. 2009;360(6):606-614. doi:10.1056/NEJMcp0808697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19196677/pubmed" id="19196677" target="_blank">19196677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852449">
<a name="32852449"></a>North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. <i>Menopause</i>. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/32852449/pubmed" id="32852449" target="_blank">32852449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35797481">
<a name="35797481"></a>North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/35797481/pubmed" id="35797481" target="_blank">35797481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28650869">
<a name="28650869"></a>North American Menopause Society (NAMS). The NAMS 2017 hormone therapy position statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. <i>Menopause</i>. 2017;24(7):728-753. doi:10.1097/GME.0000000000000921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28650869/pubmed" id="28650869" target="_blank">28650869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Searchlight.2">
<a name="Searchlight.2"></a>Oesclim (estradiol) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22296078">
<a name="22296078"></a>Palmert MR, Dunkel L. Clinical practice. Delayed puberty. <i>N Engl J Med</i>. 2012;366(5):443-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/22296078/pubmed" id="22296078" target="_blank">22296078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15240598">
<a name="15240598"></a>Piippo S, Lenko H, Kainulainen P, Sipilä I. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. <i>J Clin Endocrinol Metab</i>. 2004;89(7):3241-3247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/15240598/pubmed" id="15240598" target="_blank">15240598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34731351">
<a name="34731351"></a>Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. <i>Breast Cancer Res Treat</i>. 2022;191(2):269-275. doi:10.1007/s10549-021-06436-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/34731351/pubmed" id="34731351" target="_blank">34731351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24905063">
<a name="24905063"></a>Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. <i>J Clin Endocrinol Metab</i>. 2014;99(9):3418-3426. doi:10.1210/jc.2013-4145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/24905063/pubmed" id="24905063" target="_blank">24905063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17509587">
<a name="17509587"></a>Popat VB, Vanderhoof VH, Calis KA, Troendle JF, Nelson LM. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. <i>Fertil Steril.</i> 2008;89(2):429-433. doi:10.1016/j.fertnstert.2007.02.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/17509587/pubmed" id="17509587" target="_blank">17509587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25160739">
<a name="25160739"></a>Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. <i>Menopause</i>. 2014;21(10):1063-8. doi: 10.1097/GME.0000000000000329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/25160739/pubmed" id="25160739" target="_blank">25160739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12941676">
<a name="12941676"></a>Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. <i>JAMA</i>. 2003;290(8):1042-1048. doi:10.1001/jama.290.8.1042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/12941676/pubmed" id="12941676" target="_blank">12941676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20230416">
<a name="20230416"></a>Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. <i>J Thromb Haemost</i>. 2010;8(5):979-986. doi:10.1111/j.1538-7836.2010.03839.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/20230416/pubmed" id="20230416" target="_blank">20230416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN, Drezner MK. Menopausal hormone therapy in the prevention and treatment of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16189255">
<a name="16189255"></a>Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. <i>J Clin Endocrinol Metab</i>. 2005;90(12):6424-6430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/16189255/pubmed" id="16189255" target="_blank">16189255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117397">
<a name="12117397"></a>Rossouw JE, Anderson GL, Prentice RL, et al, “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,” <i>JAMA</i>, 2002, 288(3):321-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/12117397/pubmed" id="12117397" target="_blank">12117397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Santos.1">
<a name="Santos.1"></a>Santos XM. <i>Constitutional Delay of Puberty</i>. In Dietrich J.E.(ed.). <i>Female Puberty: A Comprehensive Guide for Clinicians</i>. New York: Springer Science+Business Media; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771112">
<a name="12771112"></a>Shumaker SA, Legault C, Rapp SR, et al, “Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,” <i>JAMA</i>, 2003, 289(20):2651-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/12771112/pubmed" id="12771112" target="_blank">12771112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27451318">
<a name="27451318"></a>Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. <i>Maturitas</i>. 2016;91:25-35. doi:10.1016/j.maturitas.2016.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/27451318/pubmed" id="27451318" target="_blank">27451318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sperling.1">
<a name="Sperling.1"></a>Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10657329">
<a name="10657329"></a>Stallard S, Litherland JC, Cordiner CM, et al, “Effect of Hormone Replacement Therapy on the Pathological Stage of Breast Cancer: Population Based, Cross Sectional Study,” <i>BMJ</i>, 2000, 320(7231):348-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/10657329/pubmed" id="10657329" target="_blank">10657329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi: 10.1210/jc.2015-2236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed January 4, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21659542">
<a name="21659542"></a>van Vlijmen EF, Veeger NJ, Middeldorp S, et al, "Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception," <i>Blood</i>, 2011, 118(8):2055-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/21659542/pubmed" id="21659542" target="_blank">21659542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33115755">
<a name="33115755"></a>Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. <i>BMJ</i>. 2020;371:m3873. doi:10.1136/bmj.m3873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/33115755/pubmed" id="33115755" target="_blank">33115755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30626577">
<a name="30626577"></a>Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. <i>BMJ</i>. 2019;364:k4810. doi:10.1136/bmj.k4810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/30626577/pubmed" id="30626577" target="_blank">30626577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34588168">
<a name="34588168"></a>Vinogradova Y, Dening T, Hippisley-Cox J, Taylor L, Moore M, Coupland C. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. <i>BMJ</i>. 2021;374:n2182. doi:10.1136/bmj.n2182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/34588168/pubmed" id="34588168" target="_blank">34588168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.3">
<a name="Novartis.3"></a>Vivelle (estradiol transdermal system) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.4">
<a name="Novartis.4"></a>Vivelle-Dot (estradiol transdermal system) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35418701">
<a name="35418701"></a>Wang X, Kapoor PM, Auer PL, et al. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. <i>Sci Rep</i>. 2022 ;12(1):6199. doi:10.1038/s41598-022-10121-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/35418701/pubmed" id="35418701" target="_blank">35418701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28383429">
<a name="28383429"></a>Wang S, Wang Y, Xu J, Chen Y. Is the oral contraceptive or hormone replacement therapy a risk factor for cholelithiasis: a systematic review and meta-analysis. <i>Medicine (Baltimore)</i>. 2017;96(14):e6556. doi:10.1097/MD.0000000000006556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28383429/pubmed" id="28383429" target="_blank">28383429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28090436">
<a name="28090436"></a>Weinand JD, Safer JD. Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals. <i>J Clin Transl Endocrinol</i>. 2015;2(2):55-60. doi:10.1016/j.jcte.2015.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28090436/pubmed" id="28090436" target="_blank">28090436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Welt.1">
<a name="Welt.1"></a>Welt CK. Management of primary ovarian insufficiency (premature ovarian failure). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28159148">
<a name="28159148"></a>Wesp LM, Deutsch MB. Hormonal and surgical treatment options for transgender women and transfeminine spectrum persons. <i>Psychiatr Clin North Am</i>. 2017;40(1):99-111. doi:10.1016/j.psc.2016.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/28159148/pubmed" id="28159148" target="_blank">28159148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8178840">
<a name="8178840"></a>Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. <i>Am J Obstet Gynecol</i>. 1994;170(5 Pt 1):1213-1223. doi:10.1016/s0002-9378(94)70129-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/8178840/pubmed" id="8178840" target="_blank">8178840</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15980 Version 628.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
